Mer­ck touts pos­i­tive PhI­II re­sults for 21-va­lent pneu­mo­coc­cal vac­cine can­di­date

Mer­ck tout­ed pos­i­tive topline re­sults on Thurs­day sug­gest­ing its ex­per­i­men­tal 21-va­lent pneu­mo­coc­cal con­ju­gate vac­cine can­di­date best­ed Pfiz­er’s 20-va­lent shot in a Phase III tri­al. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.